Combination of cancer vaccine with CD122-biased IL-2/anti-IL-2 Ab complex shapes the stem-like effector NK and CD8(+) T cells against tumor

BACKGROUND: A key to success of cancer immunotherapy is the amplification and sustenance of various effector cells. The hallmark of prominent antitumor T cells is their long-term effector function. Although interleukin (IL)-2 is an attractive cytokine, several attempts have been made towards develop...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimizu, Kanako, Ueda, Shogo, Kawamura, Masami, Aoshima, Honoka, Satoh, Mikiko, Nakabayashi, Jun, Fujii, Shin-ichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10577731/
https://www.ncbi.nlm.nih.gov/pubmed/37400134
http://dx.doi.org/10.1136/jitc-2022-006409

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10577731/
https://www.ncbi.nlm.nih.gov/pubmed/37400134
http://dx.doi.org/10.1136/jitc-2022-006409

Ejemplares similares